Skip to main content

In this Issue

  • Conversions complete, CVS brings customer service, pharmacy tools to Target shoppers

    In the slightly less than one year since CVS Health acquired all of Target’s 1,669 pharmacies and 79 retail clinics, the company has completed the process of turning them into CVS Pharmacy and MinuteClinic locations, converting as many as 150 stores per week at the peak of the integration process.

    (To download Special Report: Double Down on Health, click here.)

  • ‘Be The First’ aligns profit, philanthropic goals

    CVS Health rocked the industry in 2014 when it removed cigarettes and tobacco from its pharmacy shelves in an effort to promote health and reduce chronic illnesses associated with tobacco-use. Now, the retailer is taking yet another stance against tobacco-use with a hefty $50 million initiative to help deliver the nation’s first tobacco-free generation.

    (To download Special Report: Double Down on Health, click here.)

  • Millennials turn to external pain relief

    The demographic that’s driving much of the 10.3% growth across external analgesics may come as a surprise because it isn’t an arthritis-suffering baby boomer.

    (To view the full Category Review, click here.)

  • BI launches new combination antacid

    Boehringer Ingelheim is looking to spark some excitement across the antacids aisle with the June launch of its Duo Fusion combination antacid, “from the makers of Zantac,” which couples a fast-acting heartburn remedy with an H2 blocker to provide both immediate and longer-lasting relief from heartburn. “We saw an opportunity to trade up consumers from antacids to an H2 [blocker],” said Marc Rovner, general manager Boehringer Ingelheim Consumer Healthcare, in an interview with Drug Store News.

  • Private label, Bayer drive down internal analgesics

    Internal analgesics is slightly down in retail sales with a 0.6% decrease year-over-year. As the largest segment in internal analgesics, tablets were down 0.4%. This performance was driven down primarily by private label and Bayer products. Private-label internal analgesics were down 5%, and Bayer was down 4%. Pfizer saw no change in sales. McNeil’s return to the market did well, reflecting a 17% increase over the same time period last year. The external analgesic category was up 7% year-over-year.

  • Harry’s debut at Target attracts majority of customer base

    Not too long after Unilever’s blockbuster deal with Dollar Shave Club was announced, another online razor company made its own news. Harry’s inked a deal to sell through Target, complete with an inline presentation and an endcap decked out with a huge Harry’s signature razor.

    (To view the full Shave Report, click here.)

  • Double down on health: CVS Health is leading a retail health revolution

    Who’s leading the retail health revolution? One of the chief innovators in the transformation of U.S. health care is surely CVS Health.

    (To download Special Report: Double Down on Health, click here.)

  • Éclair Naturals sweetens bath time

    CHATSWORTH, Calif. — Natural beauty brand Éclair Naturals is leveraging the popularity of the latest bath craze with its popular and fun Fizzy Bath Cupcakes. Infused with almond oil, vitamin E and botanical extracts, Fizzy Bath Cupcakes gives consumers a natural soak, with the benefits of skin moisturizing, soothing and conditioning. Fizzy Bath Cupcakes are available in five scents: eucalyptus, rosemary and mint; grapefruit orange; lavender and vanilla; sandalwood; and breeze. All Éclair Naturals products are gluten free.

X
This ad will auto-close in 10 seconds